Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Chris Kiritsy
AddedFeb 17, 2024
UpdatedMay 31, 2026
Chris Kiritsy

Chris Kiritsy

Board Member, HTG Molecular Diagnostics

CrunchbaseLinkedIn

Chris Kiritsy's Career

HTG Molecular Diagnostics
HTG Molecular Diagnostics

Tucson, AZ, US

Board Member· Board
Arisaph Pharmaceuticals
Arisaph Pharmaceuticals

Boston, MA, US

Board Member· Board
Avaxia Biologics
Avaxia Biologics

Lexington, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Chris Kiritsy's Career

HTG Molecular Diagnostics
HTG Molecular Diagnostics
Public$106.5M1071997Tucson, AZ, US
Board Member· Board

Leadership at HTG Molecular Diagnostics

Tom DubenskyTom DubenskyBoard Member
Ann HanhamAnn HanhamBoard Member
Don HardisonDon HardisonBoard Member
Bruce SeligmannBruce SeligmannFounder
John LubniewskiJohn LubniewskiCEO
MikeMikeBoard Member
Arisaph Pharmaceuticals
Arisaph Pharmaceuticals
Series A$10M51999Boston, MA, US
Board Member· Board

Leadership at Arisaph Pharmaceuticals

Kevin FerroKevin FerroBoard Member
William BachovchinWilliam BachovchinCo-Founder
Ralf RosskampRalf RosskampBoard Member
Thomas KoestlerThomas KoestlerBoard Member

Similar to Arisaph Pharmaceuticals

Aria PharmaceuticalsAria PharmaceuticalsPalo Alto, CA, USPharmaceuticalsest. 2014Aria PharmaceuticalsPalo Alto, CA, US · est. 2014

Aria Pharmaceuticals: Pioneering novel therapies for complex diseases in preclinical stages.

Series B · $14.3M38
Riparian PharmaceuticalsRiparian PharmaceuticalsAllston-Brighton, MA, USMedical Therapiesest. 2012Riparian PharmaceuticalsAllston-Brighton, MA, US · est. 2012

Riparian Pharmaceuticals, a Boston-based biotech firm, innovates in vascular pathophysiology to treat cardiovascular and inflammatory diseases.

Series A · $3.5M8
Thetis PharmaceuticalsThetis PharmaceuticalsRidgefield, CT, USDrug Developmentest. 2011Thetis PharmaceuticalsRidgefield, CT, US · est. 2011

Thetis Pharmaceuticals: Specializing in cardio-metabolic, cancer, and autoimmune disease treatments.

Series A · $22.9M30
Aristea TherapeuticsAristea TherapeuticsSan Diego, CA, USDrugsest. 2018Aristea TherapeuticsSan Diego, CA, US · est. 2018

Aristea Therapeutics: Developing novel drugs for autoimmune and inflammatory diseases.

Series B · $117.6M75
Avaxia Biologics
Avaxia Biologics
Series D$35.3M302005Lexington, MA, US
Board Member· Board

Leadership at Avaxia Biologics

David PoorvinDavid PoorvinBoard Member
Barbara FoxBarbara FoxCo-Founder

Similar to Avaxia Biologics

Avexegen TherapeuticsAvexegen TherapeuticsSan Diego, CA, USPharmaceuticals, Therapiesest. 2014Avexegen TherapeuticsSan Diego, CA, US · est. 2014

Avexegen Therapeutics: Innovating GI health with novel therapies for Crohn's, colitis, and infant disorders.

Seed · $3.2M6
Axial TherapeuticsAxial TherapeuticsWoburn, MA, USTherapeuticsest. 2016Axial TherapeuticsWoburn, MA, US · est. 2016

Axial Biotherapeutics develops gut-restricted small molecules for treating central nervous system disorders.

Series C · $110.9M29
ACT BiotechACT BiotechSan Francisco, CA, USBiopharmaceuticalsest. 2008ACT BiotechSan Francisco, CA, US · est. 2008

ACT Biotech, Inc., an American firm, develops and markets biopharmaceuticals targeting oral cancer.

Pre-Seed · $26M30
Avior BioAvior BioDurham, NC, USDrug Developmentest. 2018Avior BioDurham, NC, US · est. 2018

Avior, a North Carolina-based biopharmaceutical company, is pioneering neuro-dermatology treatments, focusing on a unique, non-invasive oral film product for severe itch conditions.

Angel · $731k31

Chris Kiritsy's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakBo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGBoard Member · DiDi

People Similar to Chris Kiritsy

Yasunori KanekoYasunori KanekoBoard Member · Arcus BiosciencesDominic CarusoDominic CarusoBoard Member · Cystic Fibrosis FoundationKate FalbergKate FalbergBoard Member · UroGen PharmaMichael ConnMichael ConnBoard Member · FanaticsChristopher ChaiChristopher ChaiBoard Member · SurrozenJerry BatyJerry BatyBoard Member · Seraxis